Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2024

Data presentations highlight the results for FILSPARI® (sparsentan), the only approved kidney-targeted medicine for IgA nephropathy, when used as a first-line treatment, and in combination with other therapies Late-breaking presentation details outcomes of sparsentan's effect in a subgroup of high-risk patients with genetic focal segmental glomerulosclerosis SAN DIEGO, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the Company will present 11 abstracts, inc ...